28 results about "Hypromellose acetate succinate" patented technology

In some embodiments of the present disclosure, a solid dispersion is provided, comprising: lurasidone or its pharmaceutically acceptable salt and a carrier. The material of the carrier comprises polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methycellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethyl cellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

The invention relates to the technical field of empty capsules, in particular to a production process of enteric plant empty capsules. The preparation method comprises the following steps: firstly, taking hydroxypropyl methylcellulose as a main material, taking carrageenan, Tween 80 and sodium alginate as auxiliary materials, mixing the main material, the auxiliary materials and water, and carrying out glue dipping, forming, drying, demolding and cutting processes to obtain an empty capsule; the preparation method comprises the following steps: modifying chitosan by adopting sodium palmitate, so as to obtain chitosan-palmitate with hydrophobic property; and mixing the chitosan-palmitate with the hydroxypropyl methylcellulose acetate succinate to prepare a coating solution, and coating the hollow capsule to obtain a finished product. The prepared enteric plant empty capsule is high in yield, low in moisture absorption rate and long in disintegration time in gastric acid, it is ensured that effective components are released on the upper portion of the small intestine, and the absorption efficiency is improved.

The present disclosure is directed to oral dosage forms of TRβ agonist VK2809 and methods of preparing the same. The disclosure provides oral dosage forms of VK2809 with improved stability and solubility properties that allow for storage under normal conditions through the use of spray-drying with one or more polymers selected from the group consisting of: polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidinone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide) (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), copovidone, poloxamer 407, hypromellose acetate succinate (HPMCAS), polyacrylates and combinations thereof.

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

The invention discloses an ethylene propylene diene monomer for a low-pressure-change color environment-friendly O-shaped ring and a preparation method of the ethylene propylene diene monomer, and belongs to the technical field of ethylene propylene diene monomer, the ethylene propylene diene monomer for the low-pressure-change color environment-friendly O-shaped ring comprises the following components: a reinforcing agent, a plasticizer, an active agent, g-C3N4 / shell powder composite particles, a modified vulcanizing agent, a coloring agent and ethylene propylene diene monomer. According to the invention, the hydroxypropyl methylcellulose acetate succinate is introduced, so that the endurance capacity of the O-shaped ring under an extremely low temperature condition is remarkably enhanced, the application range of the O-shaped ring is widened, and the O-shaped ring can keep stable performance in a severe environment. And g-C3N4 / shell powder composite particles are ingeniously fused, so that the compression deformation rate of the material in a high-temperature environment is greatly reduced, and the recovery capability of the material after deformation is greatly improved.

The present invention relates to the technical field of hollow capsules, and specifically to a production process of enteric-coated plant hollow capsules. First, the present invention uses hypromellose as the main material, and carrageenan, Tween 80, and sodium alginate as auxiliary materials. After mixing the main material, auxiliary materials and water, hollow capsules are obtained through processes such as dipping, forming, drying, demolding, and cutting; the present invention also modifies chitosan with sodium palmitate to obtain chitosan-palmitate with hydrophobic properties; a coating solution is prepared by mixing chitosan-palmitate and hypromellose acetate succinate, and the hollow capsules are coated to obtain the finished product. The enteric-coated plant hollow capsules prepared by the present invention have a high finished product rate, a low moisture absorption rate, a long disintegration time in gastric acid, ensure the release of effective components in the upper part of the small intestine, and increase the absorption efficiency.

The invention relates to the field of medical preparations, and particularly discloses an enteric-coated hollow capsule with good friability resistance and a preparation process of the enteric-coated hollow capsule. The preparation process of the enteric hollow capsule with good friability resistance comprises the following steps: S1, preparing gelatin, a first plasticizer, an opacifying agent and a coloring agent into a glue solution; s2, hydroxypropyl methylcellulose, sodium alginate, chitosan and a second plasticizer are prepared into a first coating solution; s3, preparing a second coating solution from hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate and a neutralizer; and S4, dipping the capsule mold in the glue solution, drying, forming a capsule base, carrying out primary coating, drying, carrying out secondary coating, drying, pulling out the capsule, cutting and sleeving to obtain the enteric hollow capsule. According to the present invention, the layers of the product are tightly combined, such that the high dissolution rate, the high acid resistance and the high friability qualification rate are provided, the experimental data show that the friability qualification rate is not less than 96%, and the good friability resistance is provided.

The dispersion of amorphous uridine triacetate in hypromellose acetate succinate-MG and optionally in copovidone is disclosed. The amorphous dispersion composition enables a high loading of uridine. The amorphous dispersion composition also has good stability and oral bioavailability. The amorphous dispersion composition can be used to deliver exogenous uridine to mammalian subjects in need of exogenous uridine, such as subjects having an energy deficiency disorder or certain other conditions.

The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

The present invention belongs to the technical field of feed additives, and specifically relates to a coated tannic acid preparation for weaned piglets, and a preparation method and use thereof. In view of the existing problems that weaned piglets are prone to high diarrhea rate, low feed intake, reduced immune function, and poor growth, the present invention provides a coated tannic acid preparation for weaned piglets. The coated tannic acid preparation for weaned piglets described in the present invention comprises: by weight percentage, 70-80% of the main material and 20-30% of the auxiliary material; the main material is a mixture of tannic acid, chlorogenic acid and hesperidin; the auxiliary material is a mixture of corn starch, β-cyclodextrin, sodium alginate, palm oil, acrylic resin and hydroxypropyl methylcellulose acetate succinate. The present invention also provides a preparation method and use of the above-mentioned preparation. The preparation of the present invention can improve the palatability of feed, reduce the diarrhea rate of weaned piglets, repair damaged intestines of weaned piglets, maintain the balance of intestinal microbial cells, and improve the disease resistance of weaned piglets.

This invention discloses a pharmaceutical composition comprising a heterocyclic compound, the pharmaceutical composition comprising the following components: (a) a compound of formula (I); and (b) hydroxypropyl methylcellulose acetate succinate or copovidone; wherein components (a) and (b) are mixed and subjected to thermal melt extrusion, wherein the weight ratio of component (b) to component (a) is 0.4 to 0.8. The pharmaceutical composition of this invention exhibits stable storage over extended periods under conditions of room temperature and high relative humidity, and demonstrates significantly improved dissolution performance.

The invention belongs to the technical field of enteric capsule preparations, and particularly relates to a one-step formed enteric gelatin hollow capsule and a preparation method thereof.The enteric gelatin hollow capsule is prepared from, by weight, 80-150 parts of gelatin, 5-20 parts of plasticizer, 0.1-2 parts of opacifying agent, 0.01-2 parts of pigment and 150-300 parts of enteric material solution, the enteric-coated material is selected from a composition of at least two of cellulose acetate titanate, cellulose acetate ester, hydroxypropyl methylcellulose acetate succinate, low-methoxy pectin, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, lac, acrylic resin, and a copolymer of methyl methacrylate and methyl acrylate. According to the invention, through innovation in enteric-coated materials and preparation methods, organic solvents are not needed in preparation, the problems of waste liquid pollution and drug safety in the production and preparation process can be greatly reduced, and the prepared hollow capsule is safe and pollution-free and can be used for treatment of intestinal drugs.

The invention discloses a pharmaceutical composition containing a heterocyclic compound. The pharmaceutical composition comprises the following components: (a) a compound of formula (I); and (b) hydroxypropyl methylcellulose acetate succinate or copovidone; wherein the component (a) and the component (b) are mixed and subjected to hot melt extrusion, and the weight ratio of the component (b) to the component (a) is 0.4-0.8. The pharmaceutical composition disclosed by the invention can be stably stored for a long time under the conditions of room temperature and relatively high relative humidity, and has a remarkable and better dissolution effect. # imgabs0 #

One embodiment of the present invention provides a posaconazole-containing solid dispersion that suppresses the delayed dissolution of posaconazole during the storage period after manufacturing or the period until administration of a posaconazole-containing formulation. Alternatively, one embodiment of the present invention provides a posaconazole-containing formulation in which the delayed dissolution of posaconazole during the storage period after manufacturing or the period until administration is suppressed. [Solution] A posaconazole-containing solid dispersion according to one embodiment of the present invention comprises posaconazole, hypromellose acetate succinate, and hydroxypropyl cellulose having a viscosity of 6 mPa·s or more and 10 mPa·s or less in a 2% aqueous solution at 20°C and an average molecular weight of 140,000.

This application relates to the field of medical preparations, specifically disclosing an enteric-coated empty capsule with good brittleness resistance and its preparation process. The preparation process of an enteric-coated empty capsule with good brittleness resistance is as follows: S1, gelatin, a first plasticizer, a light-blocking agent, and a colorant are prepared into a glue solution; S2, hydroxypropyl methylcellulose, sodium alginate, chitosan, and a second plasticizer are prepared into a first coating solution; S3, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, and a neutralizing agent are prepared into a second coating solution; S4, the capsule mold is dipped in the glue solution, dried to form a capsule base, first coating, dried, second coating, dried, capsule removed, cut, and assembled to obtain the enteric-coated empty capsule. The product of this application has a tight bond between the layers, thus possessing high dissolution rate, acid resistance, and brittleness qualification rate. Experimental data shows that its brittleness qualification rate is not less than 96%, exhibiting good brittleness resistance.

The invention relates to the field of pharmaceutical preparations, in particular to butanedisulfonic acid ademetionine enteric-coated tablets and a preparation method thereof. The invention provides a butanedisulfonic acid ademetionine enteric-coated tablet. The butanedisulfonic acid ademetionine enteric-coated tablet comprises a tablet core and an enteric coating layer, wherein the tablet core comprises butanedisulfonic acid adenosyl methionine, glyceryl behenate, a filling agent, a disintegrating agent and a lubricating agent; the enteric coating layer comprises a coating premix; the coating premix comprises hydroxypropyl methylcellulose acetate succinate and an anhydrous solvent. The ademetionine butanedisulfonate enteric-coated tablet obtained by matching the glyceryl behenate and the hydroxypropyl methylcellulose acetate succinate is lower in water content, degradation of S-S ademetionine and increase of related substances are not obvious under an accelerated test condition, the product stability is better, and the medication safety of a patient can be better ensured.

The application belongs to the technical field of pharmaceutical preparations and relates to a preparation method of apaziquone tablets. The preparation method comprises the following steps: (1) preparing a solution containing apaziquone and hydroxypropyl methyl cellulose acetate succinate; (2) using part of microcrystalline cellulose as a substrate, one-step granulation is performed on the solution to obtain granules; (3) the granules are crushed to obtain fine granules; and (4) the fine granules, the remaining microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate are mixed and then compressed into a tablet core. According to the preparation method, on the basis of a selected prescription, a spray drying device or a hot melt extrusion device does not need to be introduced, dry granulation or drug particle size control does not need to be performed, one-step granulation is performed on a fluidized bed, the process is highly accessible, the cost is lower, and the product has a dissolution curve basically consistent with that of an original drug.

To provide oral dosage forms and methods useful in treatment of abnormal cell growth such as cancer in mammals, in particular in humans.SOLUTION: In one aspect, the invention comprises a composition, e.g., pharmaceutical composition comprising VS-6063 (e.g., VS-6063 free base), or a pharmaceutically acceptable salt thereof (e.g., VS-6063 hydrochloride), e.g., admixed with an excipient (e.g., a binder, e.g., a polymer, e.g., a precipitation inhibitor, e.g., Hydroxypropyl Methylcellulose. (HPMC) or Hypromellose (e.g., Hydroxypropyl Methylcellulose Acetate Succinate (HPMC-AS) or Hypromellose Acetate Succinate, e.g., HPMCAS-H, HPMCAS-M, HPMCAS-HF); e.g., polyol (e.g., mannitol-starch (e.g., Pearlitol Flash), mannitol, sorbitol)).SELECTED DRAWING: None

The invention discloses tiamulin fumarate tablets capable of improving bioavailability and a preparation method of the tiamulin fumarate tablets, and belongs to the technical field of veterinary drug preparations. Every 100 kg of the tiamulin fumarate tablet is mainly prepared from the following raw materials in parts by weight: 10 to 30 kg of tiamulin fumarate, 28 to 35 kg of Soluplus, 1.2 to 2.0 kg of silicon dioxide, 0.5 to 1.1 kg of N-trimethyl chitosan (TMC), 16 to 20 kg of HPMC-AS, 3.2 to 4.0 kg of triethyl citrate, 16 to 25 kg of microcrystalline cellulose (PH102) and 3.1 to 4.3 kg of croscarmellose sodium. According to the invention, a composite enteric-solubilization-infiltration promotion system is adopted, and the innovative process of a solubilization inner core adopts co-grinding of a main drug and Soluplus, so that the water solubility of the drug is fully improved; the enteric-coated layer adopts HPMC-AS (hydroxypropyl methylcellulose acetate succinate) to solve the problem of gastric acid degradation and reduce the gastric degradation rate, so that drugs are accurately released in intestinal tracts, and the bioavailability is improved; the penetration enhancer chitosan derivative N-trimethyl chitosan (TMC) is added, so that the intestinal mucosa permeability is enhanced, and the intestinal absorption rate is increased.

The present invention provides a fluorouracil tablet and a preparation method. Fluorouracil tablets of the present invention include a core and a coating layer, wherein the core includes the following raw materials: fluorouracil, starch, starch slurry, magnesium stearate, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone; the coating layer is made of the following excipients: pullulan, hydroxypropyl methylcellulose acetate succinate, mannitol, sodium stearate fumarate; the coating layer is made of the following excipients in weight proportion: 25-35 parts of pullulan, 18-22 parts of hydroxypropyl methylcellulose acetate succinate, 8-12 parts of mannitol, and 4-6 parts of sodium stearate fumarate. The fluorouracil tablets prepared by the present invention can better stably enter the intestine, meet the requirements of enteric-coated tablets, and have low impurity content and good stability, which is conducive to reducing the occurrence of adverse reactions, better improving the drug safety of fluorouracil, and at the same time conducive to the performance of drug efficacy.

A solid dispersion is provided, comprising: lurasidone or its pharmaceutically acceptable salt and a carrier. The material of the carrier comprises polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methycellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethyl cellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

This application, which belongs to the field of microbiology, discloses an albendazole solid dispersant, its preparation method, and use. The albendazole solid dispersant comprises albendazole, glyceryl monostearate, and hypromellose acetate succinate; the albendazole is present in an amorphous state in the albendazole solid dispersant. This dispersant significantly increases the solubility of albendazole in water by 3.15 times, effectively prevents drug release in acidic environments, and maintains slow drug release in weakly alkaline environments. The invention also provides a preparation method and use of the albendazole solid dispersant.

The invention discloses a buccal product and a preparation method thereof, and relates to the technical field of smokeless products, the pH detection value of the buccal product is smaller than 7, the buccal product comprises an active agent source, a film-forming agent, an additive and an acid-base regulator, the active agent source comprises an active agent and a coating layer coating the surface of the active agent, and the coating layer comprises a film-forming agent, a film-forming agent, an additive and an acid-base regulator. The coating layer comprises hydroxypropyl methylcellulose acetate succinate; the hydroxypropyl methylcellulose acetate succinate in the coating layer can be dissolved and release an active agent in the pH neutral environment of the oral cavity, can keep a stable state in the pH acidic environment of the stomach, and cannot be dissolved and release the active agent, so that the probability of stomach spasm caused by the active agent in the buccal product is reduced, and the safety of the oral product is improved. Therefore, the discomfort of consumers taking the buccal product is reduced, and the safety of the buccal product provided by the embodiment of the invention is improved.

The invention belongs to the field of medicine preparation, and particularly relates to a preparation method of a sustained-release famciclovir tablet for treating feline herpes virus infection, the preparation method is used for preparing the sustained-release famciclovir tablet, and the preparation method comprises the following steps: preparation of quick-release layer particles, preparation of sustained-release layer particles, double-layer tabletting and coating. Three-stage drug release is realized by preparing the double-layer tablet core containing the quick release layer and the slow release layer and combining the pH responsive coating layer. The quick-release layer and the slow-release layer are granulated by adopting specific auxiliary materials according to a certain ratio, and are subjected to fluidized bed coating by using a coating solution containing hydroxypropyl methylcellulose acetate succinate after double-layer tabletting. The prepared sustained-release tablet is not released or is released in a small amount in the stomach, is continuously released in the small intestine and maintains drug release in the colon for 12 hours, the in-vitro release degree conforms to an ideal curve, the blood concentration can be maintained for a long time, meanwhile, in-vivo drug conversion supersaturation caused by excessive drug release in a short time is avoided, and the drug utilization efficiency is improved.

Disclosed is a solid dispersion containing the following components (a), (b), and (c). (a) Deramanib; (b) at least one substance selected from the group consisting of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and a vinyl pyrrolidone-vinyl acetate copolymer; and (c) at least one substance selected from the group consisting of hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.

The application relates to the technical field of pharmaceutical auxiliaries, and particularly discloses an enteric plant capsule and a preparation method thereof. The enteric plant capsule comprises a film-forming material, an enteric coating mixed solution and an ethyl cellulose aqueous solution; the enteric coating mixed solution comprises 50-120 parts of hydroxypropyl methyl cellulose acetate succinate, 50-120 parts of hydroxypropyl methyl cellulose phthalate and 200-500 parts of a sodium hydroxide aqueous solution; the mass concentration of the sodium hydroxide aqueous solution is 0.04-0.4 mg / L; and the preparation method is as follows: the prepared enteric coating mixed solution is added into the prepared film-forming material, vacuum extraction is carried out at 60-70 DEG C and a vacuum degree of 0.065-0.092 MPa for 15-30 min, the prepared ethyl cellulose aqueous solution is added, and a glue solution is obtained; the glue solution is subjected to glue melting and glue dipping forming, and then drying, so that the enteric plant capsule with low water content, stable properties and high storage stability is obtained.

There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability. They can be used to deliver exogenous uridine to a mammalian subject in need thereof, for example a subject who has an energy failure disorder or certain other conditions.

The fluoxetine hydrochloride long-acting tablet comprises a tablet core, a common film coating layer and an enteric coating layer, and is specifically characterized in that (1) the tablet core comprises a solid dispersion prepared from fluoxetine hydrochloride and hydroxypropyl methylcellulose acetate succinate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, lactose, pregelatinized starch and magnesium stearate; (2) the common film coating layer contains hydroxypropyl methyl cellulose and succinic acid; (3) the enteric coating layer is composed of enteric acrylic resin, sodium alginate, soluble calcium salt CaCl2, glycerin and talcum powder, and the invention discloses a preparation method of the fluoxetine hydrochloride long-acting tablet, the fluoxetine hydrochloride long-acting tablet prepared by the invention can reduce the administration frequency, improve the medication safety, better meet the medication requirement, meet the depression remission period and improve the bioavailability of the fluoxetine hydrochloride long-acting tablet. And the drug can be used for consolidation period treatment or maintenance period treatment, and has very important clinical value.